{"id":40932,"date":"2021-08-01T06:19:30","date_gmt":"2021-08-01T06:19:30","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40932"},"modified":"2021-08-01T10:19:31","modified_gmt":"2021-08-01T10:19:31","slug":"who-approves-chinese-vaccines-for-emergency-use","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40932","title":{"rendered":"WHO approves Chinese vaccines for emergency use"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" alt=\"Hearts flanking a virus\" width=\"231\" height=\"142\" \/><\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\">On 1 June 2020, the WHO approved the Chinese CoronaVac (Sinovac) vaccine against COVID-19. [1]<\/span><\/strong><\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">This was based on limited research that included 51% efficacy against symptomatic infection and 100% efficacy at preventing hospitalisation and death.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Phase 3 studies are currently ongoing in Brazil, Chile, Indonesia, and Turkey and results from a large prospective national vaccine programme in Chile were just published in the NEJM. [2]<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">This is the second Chinese vaccine to be given WHO emergency use approval. On 7 May 2020, the WHO approved the Sinopharm vaccine developed by the <\/span>Beijing Institute of Biological Products. [3]<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Both vaccines have already been widely used in low-income countries. However, WHO approval means they can be included in the international COVAX programme.\u00a0<\/span>Both vaccines use inactivated virus.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The WHO have also approved vaccines by Pfizer, AstraZeneca, Johnson &amp; Johnson, Moderna and the Serum Institute of India (CoviShield). [4]<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreferences\"><span lang=\"EN-US\">References<\/span><\/p>\n<\/div>\n<div>\n<ol>\n<li class=\"HTBreferences\"><span lang=\"EN-US\">WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. (1 June 2021).<br \/>\n<\/span><a href=\"https:\/\/www.who.int\/news\/item\/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations\">https:\/\/www.who.int\/news\/item\/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations<\/a><\/li>\n<li class=\"HTBreferences\">Jara A et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. NEJM. DOI: 10.1056\/NEJMoa2107715. (7 July 2021).<br \/>\n<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2107715\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2107715<\/a><\/li>\n<li class=\"HTBreferences\">WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. (7 May 2021).<br \/>\n<a href=\"https:\/\/www.who.int\/news\/item\/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations\">https:\/\/www.who.int\/news\/item\/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations<\/a><\/li>\n<li class=\"HTBreferences\">WHO. Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process. (2 July 2021).<br \/>\n<a href=\"https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_02July2021.pdf\">https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_02July2021.pdf<\/a> (PDF)<\/li>\n<\/ol>\n<p><em>This report was first published on 7 July 2021.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 1 June 2020, the WHO approved the Chinese CoronaVac (Sinovac) vaccine against COVID-19. [1] This was based on limited research that included 51% efficacy against symptomatic infection and 100% efficacy at preventing hospitalisation and death. &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-40932","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40932"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40932\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}